ALLO-715 Utilizes Gene-Editing of TRAC and CD52 Loci to Enable Allogeneic CAR T Therapy ALLO-715 will be Evaluated in Combination with ALLO-647, Allogene’s Proprietary anti-CD52 Antibody as Part of the Lymphodepletion Regimen  Allogene Plans to Initiate the UNIVERSAL Study for ALLO-715 in

SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at three investor

Initiated ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Investigational New Drug (IND) Application Submitted to the U.S. Food & Drug Administration ( FDA ) for ALLO-715 Targeting BCMA for the Treatment of Patients with Relapsed/Refractory Multiple

Newly Appointed Members Include Robert Abraham, Ph.D., Malcolm K. Brenner, M.D., Ph.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D. SOUTH SAN FRANCISCO, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today

Anti-BCMA AlloCAR T Cells Maintained Phenotype and Sustained Potent Anti-Tumor Responses After Scaled-Up Manufacturing ALLO-715 Investigational New Drug Application and Phase 1 Trial Initiation Expected in 2019 SOUTH SAN FRANCISCO, Calif. , April 15, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics,

SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Jefferies

Anti-CD70 AlloCAR T™ Could Be Optimized to Eliminate Both CD70 Low and High Expressing Target Cells, and Manufactured in a Large-Scale Process CD70, Present on Both Hematologic Malignancies and Solid Tumors, May Facilitate Translation of AlloCAR T™ to Solid Tumors SOUTH SAN FRANCISCO, Calif.

Phase 1 ALLO-501 Clinical Trial On-Track for Initiation in 1H 2019 Trial Includes Dose Escalation to Determine the Optimal Dose of ALLO-501 and Use of ALLO-647 for Lymphodepletion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Recent Highlights Include a Successful IPO, Clearance

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today